Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.

@article{Morrison2007EffectsOE,
  title={Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.},
  author={Larry E Morrison and Susan S. Jewell and L. Josephine Usha and Beth A Blondin and Ruta D. Rao and Bita Tabesh and M Kemper and Marta Batus and John Sayler Coon},
  journal={Genes, chromosomes & cancer},
  year={2007},
  volume={46 4},
  pages={
          397-405
        }
}
Trastuzumab is widely used for advanced breast cancer patients with ERBB2-amplified tumors. Nevertheless, over half of these patients do not have an objective response. One reason may be altered expression of genes that might compensate for ERBB2 inhibition. We previously mapped the gene-rich region of chromosome 17 telomeric to ERBB2, and reported considerable variability in the telomeric extent of the ERBB2 amplicon. Here we examined whether the variable amplicon size may be associated with… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS